Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Liquidia Corporation
LQDA
NASDAQ·Healthcare·Biotechnology·Mkt cap $7.1B
$78.93
▼ -0.49%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$11.86 - $80.69
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 557.7% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary LiquidiaFill technology for advanced drug delivery
- First-mover advantage with YUTREPIA inhaled formulation in PAH market
- Established distribution network for generic treprostinil generating cash flow
- Specialized expertise in pulmonary and cardiovascular disease treatments
Bear Case
2 risks
- Low volatility (beta 0.6).
- Growth premium of 1.7x vs Biotech & Therapeutics peers. Elevated but may be justified by growth trajectory.
Growth
Strong growth ahead
YUTREPIA commercialization and market penetration in PAH patient population
Value
Growth premium of 1.7x vs Biotech & Therapeutics peers. Elevated but may be justified by growth trajectory.
Momentum
Hot
+110.5% over 3m
Quality
Excellent
High-growth business (500% revenue growth, 92% gross margin). Profitable with strong growth momentum.
Dividend
None
No dividend
Smart-money signal
Who's buying LQDA right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: May 6, 2026
MAY 11, 2026
Reported EPS of $0.52 vs $0.41 consensus (+26.8% surprise). Revenue of $132.9M vs $119.4M expected (+11.2%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Q2 26
+26.8%
Next: May 6, 2026
Revenue trend · last 8Q
—
—
-36%
+5%
+142%
+1122%
+3055%
+4158%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$3.7M
$4.4M
$2.9M
$3.1M
$8.8M
$54.3M
$92.0M
$132.9M
Margins · last 8Q
Gross
—
Operating
—
Profit
39.8%
Wall Street consensus
3 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
$62.00
▼ -21.4% vs $78.93
Latest: BTIG · Jun 22, 2026
3 analysts covering